Clovis Story

<div class='circular--portrait' style='background:#82ADFD;color: #ffffff;font-size:4em;'>CO</div>
CLVS -- USA Stock  

USD 5.67  0.11  1.90%

As many millenniums are trying to avoid healthcare space, it makes sense to sum up Clovis Oncology a little further and try to understand its current market patterns. We are going to address the reasons why we are still confident in anticipation of a recovery. The returns on investing in Clovis Oncology and the market returns of the last few months appear uncorrelated to each other. Weak basic indicators of the enterprise may also connote signs of long-running losses for Clovis retail investors. The next fiscal quarter end is expected on the 31st of March 2021. The stock is currently experiencing an active upward rally.
Published over a month ago
View all stories for Clovis Oncology | View All Stories
Will Clovis Oncology (NASDAQ:CLVS) price continue to spike in April?
This firm's average rating is Sell from 5 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Clovis Oncology market sentiment investors' perception of the future value of Clovis. Let us look at a few aspects of Clovis technical analysis. About 61.0% of the company shares are held by institutions such as insurance companies. Clovis Oncology recorded a loss per share of 4.38. The entity had not issued any dividends in recent years.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Clovis Oncology. In general, we focus on analyzing Clovis Oncology stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Clovis Oncology's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Clovis Oncology's intrinsic value. In addition to deriving basic predictive indicators for Clovis Oncology, we also check how macroeconomic factors affect Clovis Oncology price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Clovis Oncology's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Clovis Oncology in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Clovis Oncology. Your research has to be compared to or analyzed against Clovis Oncology's peers to derive any actionable benefits. When done correctly, Clovis Oncology's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Clovis Oncology.

How does Clovis Stands against Peers?

Analyzing Clovis Oncology competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Clovis Oncology across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Clovis Oncology Competition Details

How Clovis utilizes its cash?

To perform a cash flow analysis of Clovis Oncology, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Clovis Oncology is receiving and how much cash it distributes out in a given period. The Clovis Oncology cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Clovis Oncology Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. Clovis Oncology reported last year Net Cash Flow from Operations of (252.73 Million)

Closer look at Clovis Oncology Semi Deviation

Clovis Oncology has current Semi Deviation of 4.7. Semi-deviation provides a good measure of downside risk for a equity or a portfolio. It is similar to standard deviation, but it only looks at periods where the returns are less than the target or average level.

Semi-deviation is the square root of semi-variance. Semi-variance is calculated by averaging the deviations of returns that have a result that is less than the mean.

Semi Deviation 
SQRT = Square root notation
SV =   Clovis Oncology semi variance of returns over selected period
Let's now compare Clovis Oncology Semi Deviation to its closest peers:

Our take on today Clovis Oncology spike

Kurtosis is down to 0.35. It may connote a possible volatility fall. Clovis Oncology is displaying above-average volatility over the selected time horizon. Investors should scrutinize Clovis Oncology independently to ensure intended market timing strategies are aligned with expectations about Clovis Oncology volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Clovis Oncology's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Clovis Oncology's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Perspective on Clovis Oncology

While some firms under the biotechnology industry are still a bit expensive, Clovis Oncology may offer a potential longer-term growth to retail investors. To conclude, as of the 19th of March 2021, we believe that at this point, Clovis Oncology is unstable with high probability of distress within the next 2 years. From a slightly different point of view, the entity appears to be undervalued. However, our primary 30 days 'Buy-vs-Sell' recommendation on the enterprise is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Clovis Oncology. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to